Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Studying people’s experience of covid-19 vaccination – Vac4covid

Written by | 6 Apr 2021

Interview and article by Christine Clark. The Vac4covid study has been designed to provide important data about the safety and effectiveness of covid-19 vaccines. IMI interviewed Mr Gavin… read more.

ASHP publishes reports exploring pharmacy’s role in future of healthcare delivery

Written by | 1 Apr 2021

ASHP (American Society of Health-System Pharmacists) today announced the publication of two landmark reports that articulate a futuristic vision for pharmacy practice, including expanded roles for the pharmacy enterprise… read more.

AbbVie announces extension of review for supplemental NDA of upadacitinib to treat psoriatic arthritis

Written by | 26 Mar 2021

AbbVie announced that the FDA has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in the treatment of adult patients with active psoriatic… read more.

EMA backs six new medicines

Written by | 14 Mar 2021

Article written by Gary Finnegan. The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended six medicines for approval at its February 2021 meeting:

TicoVac filed with FDA for tick-borne encephalitis – Pfizer

Written by | 2 Mar 2021

Pfizer announced that the FDA accepted for Priority Review the company’s Biologics License Application (BLA) for TicoVac, its tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE… read more.

Amgen submits supplemental NDA for Otezla for adults with mild-to-moderate plaque psoriasis

Written by | 1 Mar 2021

Amgen announced the submission of a supplemental New Drug Application (sNDA) to the FDA for Otezla (apremilast) for the treatment of adults with mild-to-moderate plaque psoriasis who are… read more.

EU approves Yuflyma for multiple chronic inflammatory diseases – Celltrion Healthcare

Written by | 28 Feb 2021

Celltrion Healthcare announced that on February 11th, the European Commission (EC) has granted marketing authorisation for Yuflyma (CT-P17), an adalimumab biosimilar, across all thirteen intended indications for the… read more.

Medtronic announces voluntary recall of unused Valiant Navion Thoracic stent graft system

Written by | 24 Feb 2021

Medtronic plc has voluntarily issued a global recall of unused Medtronic Valiant Navion thoracic stent graft system and informed physicians to immediately cease use of the device until… read more.

CHMP recommends approval of Ontozry for focal – onset (partial-onset) seizures – SK Biopharmaceuticals

Written by | 12 Feb 2021

SK Biopharmaceuticals announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use.

Study estimates that, without vaccination, mortality in children under five would be 45% higher in low-income and middle-income countries

Written by | 9 Feb 2021

A new modelling study has estimated that from 2000 to 2030 vaccination against 10 major pathogens

Genetic screening before prescribing could benefit millions

Written by | 6 Feb 2021

Four million UK patients could benefit annually from genetic testing before being prescribed common medicines, according to new research from the University of East Anglia (UEA) in collaboration… read more.

GERPAC highlights 3: Bacteriophage-loaded hydrogel

Written by | 18 Dec 2020

Article written by Christine Clark A bacteriophage-loaded hydrogel proved to be effective treatment for a chronically infected knee prosthesis, according to Thomas Briot and colleagues (Red Cross Hospital,… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.